Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444665 · ClinicalTrials.gov registry record · Phase 4
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
A Phase 4 study of Glaucoma, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 750
- Enrollment target
- 1
- Study location
NCT00444665 is a Phase 4 study of Glaucoma that has completed, run by Alcon Research. The registered enrollment target is 750 participants, below the 902-participant average among 92 other Glaucoma trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00444665, a Phase 4 study of Glaucoma, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.
Conditions Studied
Interventions
- DRUG Travatan-Z
Study Locations (1)
Minnesota
- Fridley - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00444665
The ClinicalTrials.gov registry entry for NCT00444665 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 902-participant average among 92 other Glaucoma trials with a reported enrollment target (17% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Travatan-Z is the first listed.
NCT00444665 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00444665 about?
NCT00444665 is a clinical study titled "Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy". Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.
What is the current status of trial NCT00444665?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 750 participants. The study started on 2007-05. Estimated completion is 2007-08.
What conditions does trial NCT00444665 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00444665?
The interventions under investigation include: Travatan-Z (DRUG).
Who is sponsoring clinical trial NCT00444665?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00444665 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.